PRP and G‑CSF for Thin Lining — Dual Guide

Key Takeaways

• Thin endometrium is a key factor in failed implantation
• PRP (Platelet-Rich Plasma) and G‑CSF (Granulocyte Colony-Stimulating Factor) are emerging therapies
• PRP stimulates endometrial growth and blood flow
• G‑CSF modulates immune response and enhances receptivity
• Combined therapy can improve IVF and surrogacy outcomes

A receptive endometrium is critical for successful embryo implantation. When the lining is too thin (<7 mm), implantation rates drop, and miscarriage risk increases.

PRP and G‑CSF therapy are advanced strategies that help rejuvenate the endometrium and enhance implantation potential. For intended parents, these therapies offer renewed hope for successful IVF. For gestational surrogates, optimized lining supports safer, more predictable pregnancies. This guide explains how PRP and G‑CSF work, their benefits, and what patients can expect.

Understanding Thin Endometrium

Thin endometrium may result from:

• Hormonal imbalance
• Previous uterine surgeries
• Poor blood flow
• Age-related decline

Symptoms are not obvious, but ultrasound measurement before transfer helps clinicians identify the issue.

What Is PRP Therapy for Thin Lining?

Platelet-Rich Plasma (PRP) is derived from the patient’s own blood, concentrating growth factors that stimulate tissue repair.

How PRP Works

• Blood is drawn and centrifuged to extract platelets
• Platelets contain growth factors that promote angiogenesis and tissue regeneration
• PRP is infused into the uterine cavity to improve endometrial thickness and receptivity

Benefits

• Non-invasive and autologous (from the patient)
• Improves endometrial thickness
• May enhance blood flow to the uterus
• Supports better embryo implantation

What Is G‑CSF Therapy for Thin Lining?

Granulocyte Colony-Stimulating Factor (G‑CSF) is a cytokine that stimulates stem cell mobilization and modulates immune response.

How G‑CSF Works

• Administered via intrauterine infusion or subcutaneous injection
• Enhances endometrial receptivity
• Improves microcirculation and immune environment
• Supports embryo adhesion

Benefits

• Helps patients with recurrent implantation failure
• May improve pregnancy rates
• Safe and well-tolerated in surrogacy cycles

PRP vs G‑CSF: Comparison

---

Who May Benefit?

• Women with thin endometrium (<7 mm)
• Patients with recurrent implantation failure
• Intended parents using gestational surrogacy
• Cases where conventional hormonal therapy is insufficient

Role in Gestational Surrogacy

Gestational surrogates with thin lining can benefit from PRP or G‑CSF therapy, ensuring:

• Safer and predictable embryo transfer
• Improved implantation rates
• Reduced risk of cycle cancellation

Case Study

Background:
A gestational surrogate had repeated FET failures due to thin endometrium.

Intervention:
PRP infusion followed by G‑CSF administration before the next embryo transfer.

Outcome:

• Endometrium improved from 6 mm to 9 mm
• Successful embryo transfer
• Healthy ongoing pregnancy

Testimonials

Intended Parent – USA

“Using PRP and G‑CSF made the difference for us. Our surrogate’s lining improved, and we finally had a positive transfer.”

Gestational Surrogate – Canada

“The therapy was simple, and knowing it supported embryo implantation gave me peace of mind.”

Fertility Specialist

“PRP and G‑CSF are game-changers for patients struggling with thin endometrium or repeated implantation failures.”

Expert Quote

“Combining PRP and G‑CSF can rejuvenate the endometrium, creating a more receptive environment for embryo implantation, especially in surrogacy cycles.”
— Dr. Meera Joshi, Reproductive Endocrinologist

Related Links

• Endometrial Optimization in Gestational Surrogacy
• Recurrent Implantation Failure Solutions
• Advanced IVF Therapies
• Embryo Transfer Protocols

Glossary

• PRP: Platelet-Rich Plasma, rich in growth factors
• G‑CSF: Granulocyte Colony-Stimulating Factor, improves endometrial receptivity
• Thin Endometrium: Endometrial lining <7 mm
• Implantation: Embryo attaching to the uterus
• FET: Frozen Embryo Transfer

Frequently Asked Questions (FAQ)

Q. Are PRP and G‑CSF safe for surrogates?

Ans : Yes, both are minimally invasive and well-tolerated.

Q. How is PRP prepared?

Ans : Blood is drawn from the patient, centrifuged, and platelets are concentrated for infusion.

Q. Can PRP alone improve thin lining?

Ans : Often yes, but combining with G‑CSF may enhance results.

Q. How is G‑CSF administered?

Ans : Via intrauterine infusion or subcutaneous injection.

Q. How soon is improvement seen?

Ans : Typically within a few days to a week before embryo transfer.

Q. Does insurance cover these therapies?

Ans : Coverage varies and is often out-of-pocket.

Q. Are there any side effects?

Ans : Minimal; mild cramping or injection site discomfort may occur.

Q. Can it help recurrent implantation failure?

Ans : Yes, especially when thin endometrium is a contributing factor.

Q. Is this therapy experimental?

Ans : PRP and G‑CSF are increasingly used clinically, though research is ongoing.

Q. How long before transfer should therapy be done?

Ans : Usually 1–3 days prior, depending on the protocol.

Q. Can frozen embryos be used after therapy?

Ans : Yes, FET can proceed as planned.

Q. Who decides if PRP or G‑CSF is appropriate?

Ans : A fertility specialist evaluates endometrial thickness, history, and IVF outcomes.